BioCentury
ARTICLE | Company News

Cerecor licenses KOR antagonist from Lilly

February 21, 2015 1:42 AM UTC

Eli Lilly and Co. (NYSE:LLY) granted Cerecor Inc. (Baltimore, Md.) exclusive, worldwide rights to LY2456302, a kappa opioid receptor ( KOR) ( OPRK1) antagonist. Lilly previously developed the candidate to treat co-occurring substance abuse and mental health disorders.

Cerecor intends to start a Phase II trial in 2H15 of the candidate, renamed CERC-501, to treat nicotine dependence. Lilly is eligible for undisclosed milestones and royalties. ...